- Home
- COSM vs XFOR Comparison
COSM vs XFOR Comparison
Compare COSM & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- XFOR
- Stock Information
- Founded
- COSM 2009
- XFOR 2014
- Country
- COSM United States
- XFOR United States
- Employees
- COSM N/A
- XFOR N/A
- Industry
- COSM Other Pharmaceuticals
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COSM Health Care
- XFOR Health Care
- Exchange
- COSM Nasdaq
- XFOR Nasdaq
- Market Cap
- COSM 12.3M
- XFOR 11.3M
- IPO Year
- COSM 2013
- XFOR N/A
- Fundamental
- Price
- COSM $0.80
- XFOR $3.09
- Analyst Decision
- COSM
- XFOR Strong Buy
- Analyst Count
- COSM 0
- XFOR 3
- Target Price
- COSM N/A
- XFOR $71.17
- AVG Volume (30 Days)
- COSM 1.5M
- XFOR 10.5M
- Earning Date
- COSM 08-18-2025
- XFOR 08-26-2025
- Dividend Yield
- COSM N/A
- XFOR N/A
- EPS Growth
- COSM N/A
- XFOR N/A
- EPS
- COSM N/A
- XFOR N/A
- Revenue
- COSM $53,554,457.00
- XFOR $32,774,000.00
- Revenue This Year
- COSM $28.14
- XFOR $1,300.08
- Revenue Next Year
- COSM N/A
- XFOR N/A
- P/E Ratio
- COSM N/A
- XFOR N/A
- Revenue Growth
- COSM N/A
- XFOR 5721.31
- 52 Week Low
- COSM $0.28
- XFOR $1.35
- 52 Week High
- COSM $1.58
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- COSM 56.06
- XFOR 71.78
- Support Level
- COSM $0.74
- XFOR $1.35
- Resistance Level
- COSM $1.28
- XFOR $1.73
- Average True Range (ATR)
- COSM 0.18
- XFOR 0.27
- MACD
- COSM -0.01
- XFOR 0.16
- Stochastic Oscillator
- COSM 36.02
- XFOR 78.60
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.